



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 8526

<b>SERIAL NUMBER</b> 10/085,322	<b>FILING DATE</b> 02/28/2002 <b>RULE</b>	<b>CLASS</b> 435	<b>GROUP ART UNIT</b> 1645	<b>ATTORNEY DOCKET NO.</b> 1910
------------------------------------	---	---------------------	-------------------------------	------------------------------------

**APPLICANTS**  
Abbot F. Clark, Arlington, TX;

**\*\* CONTINUING DATA \*\*\*\*\***  
THIS APPLN CLAIMS BENEFIT OF 60/273,691 03/05/2001

**\*\* FOREIGN APPLICATIONS \*\*\*\*\***

**IF REQUIRED, FOREIGN FILING LICENSE GRANTED**  
\*\* 03/27/2002

Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance	STATE OR COUNTRY TX	SHEETS DRAWING	TOTAL CLAIMS 10	INDEPENDENT CLAIMS 2
--	------------------------	----------------	--------------------	-------------------------

Verified and Acknowledged  
Examiner's Signature ll Initials

**ADDRESS**  
Alcon, Inc.  
c/o Alcon Research, Ltd.  
Patrick M. Ryan(Q-148), R&D Council  
6201 So. Freeway  
Fort Worth, TX 76134-2099

**TITLE**  
Use of aminoglycosides to treat genetic ophthalmic diseases that are associated with premature termination mutations

<b>FILING FEE RECEIVED</b> 740	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit
-----------------------------------	---	---